Notably, EGFR-mutant NSCLCs that undergo SCLC transformation have poorer outcomes compared to their non-transformed counterparts, highlighting the aggressive clinical course associated with this adaptive phenotype [24]. This evidence concerns the gene EGFR and small cell lung carcinoma.